Afatinib Recruiting Phase 2 Trials for Rare Tumor / Refractory Tumors Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03239015Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event